TD Cowen Issues Pessimistic Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its target price reduced by equities research analysts at TD Cowen from $160.00 to $153.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s target price would suggest a potential upside of 20.94% from the stock’s current price.

Several other analysts also recently commented on ASND. Bank of America upped their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. reduced their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. StockNews.com lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Citigroup lifted their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, Wedbush restated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $126.51 on Friday. The firm’s 50 day simple moving average is $132.30 and its two-hundred day simple moving average is $132.66. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The company has a market capitalization of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its holdings in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares during the last quarter. Profund Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after buying an additional 85 shares during the period. Rhumbline Advisers increased its holdings in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after acquiring an additional 228 shares during the last quarter. Finally, Avior Wealth Management LLC grew its holdings in shares of Ascendis Pharma A/S by 3.0% during the 3rd quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock worth $1,226,000 after purchasing an additional 240 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.